Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 110,626 | $36.80 | $4,071,036.80 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · nonDerivative · entry 5 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,879 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 22,314 | $34.72 | $774,742.08 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · nonDerivative · entry 4 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,505 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 12,485 | $34.72 | $433,479.20 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,819 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
GrantCommon Stock | 45,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,304 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:32 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 144,928 | $34.59 | $5,013,059.52 |
DisclosureSEC source: 0001225208-20-003804 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 8,104 | $34.72 | $281,370.88 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · nonDerivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,322 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 7,984 | $34.72 | $277,204.48 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,426 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantCommon Stock | 17,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,410 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:34 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantCommon Stock | 21,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003805 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,323 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 23:03 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 1,409 | $35.72 | $50,329.48 |
DisclosureSEC source: 0001225208-20-003500 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,977 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 21, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 23:03 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 2,116 | $35.72 | $75,583.52 |
DisclosureSEC source: 0001225208-20-003502 · doc4.xml · nonDerivative · entry 1 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,428 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 21, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 23:03 UTC |
ROGERS DAWNExecutive Vice President
|
Tax withholdingCommon Stock | 1,015 | $35.72 | $36,255.80 |
DisclosureSEC source: 0001225208-20-003501 · doc4.xml · nonDerivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,898 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 21, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 23:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 1,574 | $35.72 | $56,223.28 |
DisclosureSEC source: 0001225208-20-003503 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,041 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 21, 2020. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 23:40 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 760 | $36.93 | $28,066.80 |
DisclosureSEC source: 0001225208-20-002406 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,550 Underlying: Common Stock · 760 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 23:40 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 177 | $36.93 | $6,536.61 |
DisclosureSEC source: 0001225208-20-002407 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common Stock · 177 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 23:40 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 2,246 | $36.93 | $82,944.78 |
DisclosureSEC source: 0001225208-20-002408 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,551 Underlying: Common Stock · 2,246 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 23:40 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 576 | $36.93 | $21,271.68 |
DisclosureSEC source: 0001225208-20-002409 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,483 Underlying: Common Stock · 576 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:38 UTC |
Fonseca LidiaExecutive Vice President
|
Tax withholdingCommon Stock | 6,043 | $37.24 | $225,041.32 |
DisclosureSEC source: 0001225208-20-001563 · doc4.xml · nonDerivative · entry 1 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,310 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 13:06 UTC |
Gottlieb ScottDirector
|
PurchaseCommon Stock | 1,000 | $37.00 | $36,996.60 |
DisclosureSEC source: 0001225208-20-001364 · doc4.xml · nonDerivative · entry 1 Gottlieb Scott · CIK 0001411359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 20:47 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 46 | $38.89 | $1,788.94 |
DisclosureSEC source: 0001225208-20-000708 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,004 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 20:47 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 18 | $38.89 | $700.02 |
DisclosureSEC source: 0001225208-20-000709 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 18 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 20:47 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 217 | $38.89 | $8,439.13 |
DisclosureSEC source: 0001225208-20-000710 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,185 Underlying: Common Stock · 217 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 20:47 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 36 | $38.89 | $1,400.04 |
DisclosureSEC source: 0001225208-20-000711 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,429 Underlying: Common Stock · 36 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:48 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 26 | $39.18 | $1,018.68 |
DisclosureSEC source: 0001225208-20-000017 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,952 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:48 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $39.18 | $156.72 |
DisclosureSEC source: 0001225208-20-000018 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,082 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:48 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 48 | $39.18 | $1,880.64 |
DisclosureSEC source: 0001225208-20-000019 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,967 Underlying: Common Stock · 48 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:48 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $39.18 | $430.98 |
DisclosureSEC source: 0001225208-20-000020 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,390 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 23:36 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 1,100.689 | $39.18 | $43,125.00 |
DisclosureSEC source: 0001225208-20-000054 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,971.518 Underlying: Common Stock · 1,100.689 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 23:36 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 877.361 | $39.18 | $34,375.00 |
DisclosureSEC source: 0001225208-20-000055 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,337.58 Underlying: Common Stock · 877.361 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 23:36 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 1,196.401 | $39.18 | $46,874.99 |
DisclosureSEC source: 0001225208-20-000056 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,926.777 Underlying: Common Stock · 1,196.401 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 23:36 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 1,068.881 | $39.18 | $41,878.76 |
DisclosureSEC source: 0001225208-20-000057 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,717.217 Underlying: Common Stock · 1,068.881 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2019 Filed Dec 31, 2019 14:24 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 9,676 | $39.32 | $380,460.32 |
DisclosureSEC source: 0001225208-19-016123 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,149 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 23:09 UTC |
YOUNG JOHN DGroup President
|
GiftCommon Stock | 1,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015862 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,825 Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 23:09 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $38.33 | $421.63 |
DisclosureSEC source: 0001225208-19-015862 · doc4.xml · derivative · entry 4 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,393 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 23:10 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 26 | $38.33 | $996.58 |
DisclosureSEC source: 0001225208-19-015863 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,951 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 23:10 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $38.33 | $153.32 |
DisclosureSEC source: 0001225208-19-015864 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,080 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 23:10 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 49 | $38.33 | $1,878.17 |
DisclosureSEC source: 0001225208-19-015865 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,923 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 15:44 UTC |
Hwang AngelaGroup President
|
GiftCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015129 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 8,532 Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 15:44 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 26 | $38.52 | $1,001.52 |
DisclosureSEC source: 0001225208-19-015130 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,920 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 15:44 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $38.52 | $154.08 |
DisclosureSEC source: 0001225208-19-015131 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,076 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 15:44 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 49 | $38.52 | $1,887.48 |
DisclosureSEC source: 0001225208-19-015132 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,873 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 15:44 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $38.52 | $423.72 |
DisclosureSEC source: 0001225208-19-015133 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,379 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 27, 2019 Filed Dec 3, 2019 20:39 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GiftCommon Stock | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015164 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,435 Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 22:19 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 27 | $37.28 | $1,006.56 |
DisclosureSEC source: 0001225208-19-014630 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,929 Underlying: Common Stock · 27 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 22:20 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $37.28 | $149.12 |
DisclosureSEC source: 0001225208-19-014631 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,074 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 22:20 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 50 | $37.28 | $1,864.00 |
DisclosureSEC source: 0001225208-19-014632 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,830 Underlying: Common Stock · 50 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 22:20 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $37.28 | $410.08 |
DisclosureSEC source: 0001225208-19-014633 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,390 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 19:56 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 26 | $38.37 | $997.62 |
DisclosureSEC source: 0001225208-19-013983 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,199 Underlying: Common Stock · 26 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 19:56 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $38.37 | $153.48 |
DisclosureSEC source: 0001225208-19-013984 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,021 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 19:56 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 49 | $38.37 | $1,880.13 |
DisclosureSEC source: 0001225208-19-013985 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,675 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.